Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.03
-0.76 (-4.04%)
May 14, 2026, 11:45 AM EDT - Market open
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
13.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.36B |
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
SMMT News
- 10 days ago - Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 10 days ago - Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright - TheFly
- 12 days ago - Summit Therapeutics falls -23.7% - TheFly
- 13 days ago - Summit Therapeutics falls -27.4% - TheFly
- 13 days ago - Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler - TheFly
- 13 days ago - Summit Therapeutics price target lowered to $31 from $32 at Clear Street - TheFly
- 13 days ago - Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c) - TheFly
- 13 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 - Business Wire